The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …

Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as
Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have …

Background Ulcerative colitis (UC) is a chronic autoimmune inflammation of the colon. The
condition significantly decreases quality of life and generates a substantial economic burden …

Background Inflammatory bowel disease poses significant social and economic burdens.
We assessed the budget impact of including the recently approved subcutaneous (SC) …

Objective Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of ulcerative
colitis (UC). The objective of this study was to evaluate the long-term cost-effectiveness of …

Objective To examine the clinical and economic impact of vedolizumab compared with
infliximab, adalimumab, and golimumab in the treatment of moderately to severely active …

Objective. The objective of this literature review was to evaluate the existing evidence
regarding the cost‐effectiveness of treatment options in IBD. Methods. A systematic review of …

Objective: To evaluate the cost effectiveness of vedolizumab vs. infliximab in the treatment of
anti-tumor necrosis factor-alpha (TNF-α)-naïve patients with moderate-to-severe active …

Background Vedolizumab (VDZ) was approved by the Japanese Ministry of Health, Labor
and Welfare in 2018 for the treatment of patients with moderate-to-severe active ulcerative …

Abstract Background and Objectives Ulcerative colitis is highly prevalent in Canada and cost-
effective ulcerative colitis therapies are warranted. Vedolizumab subcutaneous (SC) …